Akoya Biosciences Q2 2023 Earnings Report

Akoya Biosciences EPS Results

• Actual EPS: -$0.51
• Consensus EPS: -$0.44
• Beat/Miss: Missed by -$0.07
• One Year Ago EPS: N/A

Akoya Biosciences Revenue Results

• Actual Revenue: $23.52 million
• Expected Revenue: $22.17 million
• Beat/Miss: Beat by +$1.35 million
• YoY Revenue Growth: N/A

Akoya Biosciences Announcement Details

• Quarter: Q2 2023
• Date: 8/7/2023
• Time: N/A

Akoya Biosciences (NASDAQ:AKYA), a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.